CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 28, 2018--
AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that Michael
Bailey, president and chief executive officer, will participate in the
following investor conferences:
B. Riley FBR Healthcare Conference on Tuesday, September 4, 2018 at
3:25 p.m. Eastern Time. The conference is being held at the New York
Marriott East Side Hotel.
20th Annual Rodman & Renshaw Global Investment Conference, sponsored
by H.C. Wainwright & Co., LLC., on Wednesday, September 5, 2018 at
10:25 a.m. Eastern Time. The conference is being held at the St. Regis
New York Hotel.
A live webcast of Mr. Bailey’s presentation at the Rodman & Renshaw
conference can be accessed by visiting the investors section of the
Company’s website at www.aveooncology.com.
A replay of the webcast will be archived for 30 days following the
About AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc. (the “Company”) is a biopharmaceutical
company dedicated to advancing a broad portfolio of targeted medicines
for oncology and other areas of unmet medical need. The Company’s
strategy is to retain North American rights to its oncology portfolio
while securing partners in development and commercialization outside of
North America. The Company is seeking to develop and commercialize its
lead candidate tivozanib in North America as a treatment for advanced
renal cell carcinoma (“aRCC”). The Company has outlicensed tivozanib
(FOTIVDA®) for oncology in Europe and other territories outside of North
America. Tivozanib is approved in the European Union, as well as Norway
and Iceland, for the first-line treatment of adult patients with aRCC
and for adult patients who are vascular endothelial growth factor
receptor and mTOR pathway inhibitor-naïve following disease progression
after one prior treatment with cytokine therapy for aRCC. The Company
has entered into partnerships to fund the development and
commercialization of AV-203 (CAN017) and ficlatuzumab, both clinical
stage assets in oncology. The Company is currently seeking a partner to
develop the AV-353 platform, a preclinical asset, worldwide for the
potential treatment of pulmonary arterial hypertension. The Company
previously partnered with Novartis International Pharmaceutical Ltd.
(“Novartis”) to develop the AV-380 program in cachexia and other
indications. The Company has recently regained the rights to its AV-380
program for the potential treatment of cachexia and is considering a
variety of options to advance the program’s development.
For more information, please visit the Company’s website at www.aveooncology.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO that
involve substantial risks and uncertainties. All statements, other than
statements of historical fact, contained in this press release are
forward-looking statements. Actual results or events could differ
materially due to a number of important factors, including risks
discussed in the section titled “Risk Factors” in AVEO’s most recent
Annual Report on Form 10-K, its quarterly reports on Form 10-Q and its
other filings with the SEC. The forward-looking statements in this press
release represent AVEO’s views as of the date of this press release.
AVEO anticipates that subsequent events and developments may cause its
views to change. While AVEO may elect to update these forward-looking
statements at some point in the future, it specifically disclaims any
obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing AVEO’s views as of any date
other than the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180828005207/en/
Source: AVEO Pharmaceuticals, Inc.
David Pitts, 212-600-1902